Ellen Welch
PTC Therapeutics (United States)(US)
Publications by Year
Research Areas
RNA Research and Splicing, RNA and protein synthesis mechanisms, RNA modifications and cancer, Neurogenetic and Muscular Disorders Research, Muscle Physiology and Disorders
Most-Cited Works
- → PTC124 targets genetic disorders caused by nonsense mutations(2007)1,121 cited
- → SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy(2014)520 cited
- → Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial(2014)334 cited
- → PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR -G542X nonsense allele in a CF mouse model(2008)249 cited
- → Safety, Tolerability, and Pharmacokinetics of PTC124, a Nonaminoglycoside Nonsense Mutation Suppressor, Following Single‐ and Multiple‐Dose Administration to Healthy Male and Female Adult Volunteers(2007)238 cited
- → Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppression(2016)222 cited
- → Ataluren as an Agent for Therapeutic Nonsense Suppression(2012)194 cited
- → An internal open reading frame triggers nonsense-mediated decay of the yeast SPT10 mRNA(1999)107 cited
- → Nonsense-mediated mRNA Decay in Yeast(1994)106 cited
- → Spp1 (osteopontin) promotes TGFβ processing in fibroblasts of dystrophin-deficient muscles through matrix metalloproteinases(2019)95 cited